Merck & Co., Inc. Future Amortization Expense, Year Two (Deprecated 2012-01-31)
Merck & Co., Inc. (MRK) reported Future Amortization Expense, Year Two (Deprecated 2012-01-31) of $4.80 billion for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FutureAmortizationExpenseYearTwo · last filed 2012-02-28
- Merck & Co., Inc. future amortization expense, year two (deprecated 2012-01-31) for fiscal 2011 was $4.80B, a 6.67% increase from fiscal 2010.
- Merck & Co., Inc. future amortization expense, year two (deprecated 2012-01-31) for fiscal 2010 was $4.50B.
| Period end | Future Amortization Expense, Year Two (Deprecated 2012-01-31) 12 month |
|---|---|
| 2011-12-31 | $4.80B 10-K · filed 2012-02-28 |
| 2010-12-31 | $4.50B 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |